Senpoly

Senpoly is a biotechnology company based in Suzhou, China, specializing in the development of innovative therapies that target cellular senescence to treat aging-related diseases. Founded in 2021 by Dr. Daohong Zhou, a prominent figure in the field of senolytics, the company focuses on identifying and optimizing small molecules and PROTACs that selectively eliminate "zombie" senescent cells. By targeting pro-survival pathways such as BCL-XL, Senpoly aims to mitigate the chronic inflammation and tissue degeneration associated with aging. The company's current pipeline includes programs for idiopathic pulmonary fibrosis, osteoarthritis, and ophthalmic conditions, all of which are in the pre-clinical or IND-enabling stages. Senpoly's proprietary platform enables the discovery of potent senolytics with improved safety profiles, specifically addressing common side effects like thrombocytopenia. Backed by leading venture capital firms like Legend Capital and Matrix Partners China, Senpoly is a significant player in the emerging longevity biotechnology sector.